This therapeutic approach targets nucleocytoplasmic transport (NCT) dysfunction, a fundamental mechanism underlying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The nuclear pore complex (NPC) and associated transport proteins are compromised in these disorders, leading to nuclear-cytoplasmic mislocalization of RNAs and proteins, including TDP-43 and FUS.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9 | Emerging mechanism; limited therapeutic development |
| Mechanistic Rationale | 9 | Strong genetic and neuropathology evidence |
| Root-Cause Coverage | 8 | Addresses upstream nuclear integrity |
| Delivery Feasibility | 6 | Large molecules need CNS delivery; small molecules promising |
| Safety Plausibility | 7 | Nuclear transport modulators being developed in oncology |
| Combinability | 9 | Synergistic with TDP-43, FUS, C9orf72 targeted approaches |
| Biomarker Availability | 7 | Nuclear/cytoplasmic ratio of TDP-43 in CSF or neurons |
| De-risking Path | 6 | Early stage; needs validation |
| Multi-disease Potential | 8 | AD, PD, Huntington disease all show NCT defects[@lin2013] |
| Patient Impact | 9 | High unmet need in ALS/FTD |
Total Score: 78/100
| Disease | Coverage | Rationale |
|---|---|---|
| ALS | 10 | Core mechanism in sporadic and familial ALS |
| FTD | 10 | TDP-43 and FUS pathology linked to NCT dysfunction |
| AD | 6 | NPC dysfunction documented in AD models |
| PD | 5 | Some evidence of NCT impairment |
| Aging | 7 | Age-related nuclear pore alterations |
The nuclear pore complex (NPC) regulates all molecular traffic between nucleus and cytoplasm. In ALS/FTD: